Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Physician
Patient
Health Care Practitioner
Pharma / Biotech Industry
Other
Topics:
Rheumatology
•
Rheumatoid Arthritis
What is your approach to biologic therapy in older adults (80+) with RA and CKD?
Related Questions
If subdeltoid bursitis, bicipital tenosynovitis, and femoroacetabular synovitis are commonly present in PMR, why are they not included in the criteria for PMR and how are they differentiated from elderly onset RA where presentation is often atypical and more proximal?
When do you recommend initiation of targeted therapies in active RA with history of malignancy?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
How do you manage oral ulcers as a side effect from leflunomide?
When considering biologic therapy after failure of MTX or triple therapy, do you consider using Abatacept as a first line biologic?
Is it ever safe to use a biologic DMARD in a patient with RA who is on suppressive antibiotics due to a history of septic prosthetic arthritis?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
